Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis

NCT05609630 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05609630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05609630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
October 2, 2023
Completion date
June 30, 2029
Enrollment
90 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis